What is TidalSense?
Founded in 2013, TidalSense specializes in the development of AI-driven diagnostic and monitoring solutions. The company's core innovation, the N-Tidal platform, utilizes patented sensor technology to capture high-fidelity data on lung function. Unlike traditional diagnostic tools, this system offers a non-invasive, highly precise method for assessing respiratory conditions, effectively bridging the gap between complex physiological data and actionable clinical intelligence. As a key player in the health technology sector, TidalSense is currently scaling its operations to address the growing global demand for accurate, real-time respiratory diagnostics in both primary and secondary care settings.
How much funding has TidalSense raised?
TidalSense has raised a total of $28.3M across 2 funding rounds:
Other Financing Round
$9.3M
Unspecified
$19M
Other Financing Round (2023): $9.3M with participation from Downing Ventures and BGF
Unspecified (2026): $19M led by Airstream Capital, Foresight Group Holdings, Cross-Border Impact Ventures, and BGF
Key Investors in TidalSense
Airstream Capital
Airstream Capital is a private equity firm founded by experienced executives that focuses on investing in high-growth technologies and management teams, leveraging deep expertise in corporate finance to drive value.
Foresight Group Holdings
Foresight Group Holdings is a diversified, publicly traded conglomerate with a long-standing history in civil engineering and infrastructure development, providing strategic support to growing enterprises.
Cross-Border Impact Ventures
Cross-Border Impact Ventures is an impact-focused VC firm that invests in transformative health technology companies, specifically targeting innovations that improve outcomes in women, children, and adolescent health.
What's next for TidalSense?
With this latest capital injection, TidalSense is well-positioned to accelerate its commercialization strategy and expand the clinical application of its N-Tidal platform. The company is expected to focus on deepening its market penetration within the UK and international healthcare systems, while simultaneously refining its AI algorithms to enhance diagnostic sensitivity. As the firm transitions into a more mature growth phase, the strategic backing from its diverse investor base will be instrumental in navigating regulatory landscapes and scaling manufacturing capabilities to meet the needs of a global patient population. Future milestones will likely include the integration of its diagnostic suite into broader digital health ecosystems, further cementing its role as a leader in respiratory medicine innovation.
See full TidalSense company page
